OptimizeRx Corp. $OPRX Shares Acquired by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. significantly increased its stake in OptimizeRx Corp. by 25,355.6%, owning 45,820 shares worth $397,000 after purchasing an additional 45,640 shares in the 1st quarter.
• Multiple analysts have raised their price targets for OptimizeRx, with JMP Securities boosting it from $14.00 to $20.00, indicating a positive outlook with an overall consensus rating of "Moderate Buy".
• As of now, OptimizeRx shares have a market cap of $335.56 million, with a 52-week range between $3.78 and $18.96, and the stock is currently trading at $18.07.

Russell Investments Group Ltd. lifted its position in shares of OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 25,355.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,820 shares of the company's stock after purchasing an additional 45,640 shares during the period. Russell Investments Group Ltd. owned about 0.25% of OptimizeRx worth $397,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blair William & Co. IL lifted its position in OptimizeRx by 4.9% in the first quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock valued at $5,465,000 after acquiring an additional 29,648 shares during the last quarter. Squarepoint Ops LLC lifted its position in OptimizeRx by 298.8% in the fourth quarter. Squarepoint Ops LLC now owns 41,712 shares of the company's stock valued at $203,000 after acquiring an additional 31,252 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in OptimizeRx by 47.1% in the first quarter. Janney Montgomery Scott LLC now owns 124,751 shares of the company's stock valued at $1,080,000 after acquiring an additional 39,969 shares during the last quarter. Jane Street Group LLC lifted its position in OptimizeRx by 234.7% in the fourth quarter. Jane Street Group LLC now owns 72,454 shares of the company's stock valued at $352,000 after acquiring an additional 50,808 shares during the last quarter. Finally, Calamos Advisors LLC purchased a new stake in OptimizeRx in the first quarter valued at $289,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Performance

NASDAQ OPRX traded up $0.21 during trading on Friday, reaching $18.82. The company's stock had a trading volume of 351,640 shares, compared to its average volume of 468,519. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57. The firm has a market cap of $349.49 million, a price-to-earnings ratio of -34.85, a P/E/G ratio of 2.64 and a beta of 1.20. OptimizeRx Corp. has a twelve month low of $3.78 and a twelve month high of $19.25. The business's fifty day moving average price is $14.91 and its 200-day moving average price is $11.41.

Analyst Ratings Changes

A number of brokerages recently weighed in on OPRX. JMP Securities boosted their price target on shares of OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a research report on Monday, August 11th. Citigroup reissued an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Wall Street Zen raised shares of OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. B. Riley restated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Roth Capital restated a "buy" rating on shares of OptimizeRx in a research note on Friday, August 8th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $11.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.